An Immune-Related Clinical-Gene-Risk-Score (CGRS) Prognosis Model for Bladder Cancer

Abstract Immunotherapy for bladder cancer is prevalent, while the efficacy is uncertain. To predict the outcomes of immunotherapy in bladder cancer patients, we had delineated the landscape of the tumor immune microenvironment based on two independent public databases, classified the bladder cancers in the training cohort as well as the validating cohort into the immune high and immune low subtypes, and identified 23 differentially expressed immune-related genes between the two subtype patients to build a prognostic gene risk score model. We further combined the model with other clinicopathologic signatures to develop a Clinical-Gene-Risk-Score (CGRS) prognosis model and validations of the two models in independent cohorts revealed good accuracy. Our model could provide prognostic indicators and potential immunotherapeutic targets for bladder cancers.